Spyre Therapeutics (SYRE) Preferred Shares Issued (2015 - 2024)

Spyre Therapeutics (SYRE) reported Preferred Shares Issued of -$169.2 million for Q2 2024, down 180.57% on a YoY basis from $210.0 million in Q3 2023, and down 200.0% quarter-over-quarter from $169.2 million in Q1 2024.

Spyre Therapeutics (SYRE) Preferred Shares Issued (2015 - 2024) Analysis & Trends

Spyre Therapeutics has reported Preferred Shares Issued for 3 years, with the latest figure at -$169.2 million in Q2 2024.

  • For the quarter ending Q2 2024, Preferred Shares Issued fell 180.57% year-over-year to -$169.2 million; the trailing twelve-month figure through Jun 2024 stood at -$12.6 million (down 106.02% YoY), and the FY2023 full-year result was $197.4 million, changed N/A from the prior year.
  • Preferred Shares Issued for Q2 2024 stood at -$169.2 million, down from $169.2 million in the prior quarter.
  • The five-year high for Preferred Shares Issued was $210.0 million in Q2 2023, with the low at -$169.2 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Spyre Therapeutics 6.95 Bn 6.95 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 -169.21 Mn
Jun 30, 2024 -169.21 Mn
Mar 31, 2024 169.21 Mn
Mar 31, 2024 169.21 Mn
Sep 30, 2023 -12.64 Mn
Sep 30, 2023 -12.64 Mn
Jun 30, 2023 210.00 Mn
Jun 30, 2023 210.00 Mn
Sep 30, 2015 -5,000.00
Sep 30, 2015 -5,000.00
Jun 30, 2015 6,000.00
Jun 30, 2015 6,000.00
Mar 31, 2015 43.68 Mn
Mar 31, 2015 43.68 Mn